Sapien Stroke Discussion Continues With Expanded PARTNER Analysis
This article was originally published in The Gray Sheet
Executive Summary
Investigators from Edwards Lifesciences’ PARTNER clinical trial reported a more detailed analysis of the incidence of stroke in study patients treated with the firm's Sapien transcatheter valve, though there did not appear to be any major new revelations that would impact approvability.
You may also be interested in...
With FDA Questions Answered, Edwards Expects Sapien Approval “Any Day”
Edwards Lifesciences expects FDA approval of its Sapien transcatheter aortic heart valve replacement “any day,” CEO Michael Mussallem said Oct. 19.
With FDA Questions Answered, Edwards Expects Sapien Approval “Any Day”
Edwards Lifesciences expects FDA approval of its Sapien transcatheter aortic heart valve replacement “any day,” CEO Michael Mussallem said Oct. 19.
Panel Supports Sapien But Urges Cautious Rollout
Edwards Lifesciences’ Sapien transcatheter aortic valve met widespread expectations last week by gaining support for FDA approval from an agency advisory panel, but the experts urged FDA and Edwards to proceed cautiously.